- Home
- Products
- Customized ADCs
- CD5
- Anti-CD5 (Zolimomab aritox)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC
Anti-CD5 (Zolimomab aritox)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-931)
This ADC product is comprised of an anti-CD5 monoclonal antibody conjugated via a MC-Vc-PAB-DMEA-(PEG2) linker to duocarmycin SA. The duocarmycin SA is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, duocarmycin SA binds to DNA, causes DNA damage.
- ADC Target
- ADC Antibody
- ADC Linker
- ADC payload drug
- Name
- CD5
- Alternative Names
- CD5; CD5 molecule; CD5 antigen (p56 62) , LEU1; T-cell surface glycoprotein CD5; T1; CD5 antigen (p56-62); lymphocyte antigen T1/Leu-1; LEU1;
- Target Entrez Gene ID
- 921
- Target UniProt ID
- P06127
- Overview
- This gene encodes a member of the scavenger receptor cysteine-rich (SRCR) superfamily. Members of this family are secreted or membrane-anchored proteins mainly found in cells associated with the immune system. This protein is a type-I transmembrane glycoprotein found on the surface of thymocytes, T lymphocytes and a subset of B lymphocytes. The encoded protein contains three SRCR domains and may act as a receptor to regulate T-cell proliferation. Alternative splicing results in multiple transcript variants encoding different isoforms.
- Overview
- Anti-CD5 IgG1 antibody, Zolimomab aritox
- Generic name
- Zolimomab aritox
- Host animal
- Mouse
- Species Reactivity
- Human
- Name
- MC-Vc-PAB-DMEA-(PEG2)
- Description
- Peptide linkers, belonging to Enzymatically cleavable linkers, combine greater systemic stability with rapid enzymatic release of the drug in the target cell. The scission of peptidic bonds relies on lysosomal proteolytic enzymes, which have very low activities in blood due to endogenous inhibitors and the unfavorably high pH value of blood.
- Name
- duocarmycin SA
- Description
- Duocarmycins SA belong to the minor-groove-binding DNA-alkylating agents (DNA MGBA). The natural duocarmycins are isolated from the culture broth of Streptmyces sp and a series of derivatives has also been synthesized.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-TNFRSF17-VC-MMAE ADC-11 (CAT#: ADC-W-272)
- Anti-CSF2 (Namilumab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-989)
- Anti-EPCAM (Adecatumumab)-MC-MMAF ADC (CAT#: ADC-W-1072)
- Anti-TGFB1 (Metelimumab)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-1806)
- Anti-MSLN (Anetumab )-MC-MMAF ADC (CAT#: ADC-W-2561)
- Anti-ERBB2 (Margetuximab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1111)
- Anti-TAG-72 (Satumomab Pendetide)-MC-Vc-PAB-SN38 ADC (CAT#: ADC-W-2160)
- Anti-TNFSF4 (Oxelumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC (CAT#: ADC-W-1921)
- Anti-GD2 (Dinutuximab)-MC-Vc-PAB-MMAE ADC (CAT#: ADC-W-2009)
- Anti-CD22-MCC-DM1 ADC (CAT#: ADC-W-336)
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for ADC-W-931. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
Same Linker
Same Payload
| CAT# | Product Name | Linker | Payload |
| ADC-W-937 | Anti-CD5 (Telimomab aritox)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-933 | Anti-CD5 (Telimomab aritox)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-930 | Anti-CD5 (Zolimomab aritox)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-935 | Anti-CD5 (Telimomab aritox)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-929 | Anti-CD5 (Zolimomab aritox)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2553 | Anti-CD74-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2609 | Anti-ITGB3 (Tadocizumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2597 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2619 | Anti-MS4A1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2564 | Anti-MSLN (Anetumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| CAT# | Product Name | Linker | Payload |
| ADC-W-2619 | Anti-MS4A1-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2547 | Anti-CD44 (Bivatuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2603 | Anti-GPNMB (Glembatumumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2576 | Anti-SLC34A2 (Lifastuzumab )-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-2582 | Anti-CEACAM5-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.